- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02979275
Correlation of Brain and Thenar Muscle Oximetry During Cardiac Surgery With Parameters of Acute Kidney Injury
Correlation of Brain and Thenar Muscle Oximetry During Cardiac Surgery With Parameters of Acute Kidney Injury in Adult Cardiac Surgical Patients Operated on Cardiopulmonary Bypass
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The day before operation, after verification of inclusion and exclusion criteria, the visiting anesthesiologist will explain to the patient the aim of the study. By signing an informed consent the patient will be recruited into the study. On the evening before operation the patient will receive the statin in a dose taken along.
In the OR the anesthesiologist will verify if creatinin and blood urea nitrogen were measured the day before operation - if not, a blood sample for the test will be obtained and sent to perform the tests.
Before induction of anesthesia a bi-spectral index (BIS) probe will be placed on the patients forehead. Above the BIS probe a INVOS(TM) probe for brain oximetry (5100 C Cerebral/Somatic Oximeter, Somanetics, Medtronic) will be placed.
Brain oximetry by near infrared saturation (NIRS) and tissue saturation on thenar muscle will be recorded before and during operation on nine timepoints.
As NIRS and thenar muscle saturation are non-routine non-invasive methods of intraoperative monitoring, patient had to sign an informed consent to participate into the study, and ethic committee approval for the study protocol was appealed and granted.
General anesthesia will be induced by: fentanyl 0.2 mg, propofol 0.5-1.5 mg/kg in bolus 200ml/godz.; and rocuronium - 0.5 mg/kg. After induction dexamethasone will be given in a dose of 0,7-1 mg/kg. For conduction of anesthesia before cardiopulmonary bypass (CPB) sevoflurane will be added to the inhaled mixture of air and oxygen. On CPB propofol will be given iv. In case of hemodynamic instability after commencing CPB, which will require catecholamines in a cumulative dose of > 1.5 standard, or in case of trouble to commence CPB, propofol will be replaced by midazolam in a dose 0.2-0.3 mg/kg/hour.
During anesthesia, first post-operative day and hospital stay a total of 278 variables will be recorded: hemodynamic parameters, iv fluid doses, inotropes, vasopressors, diuretics, urine output, transfusions, etc.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Pomorskie
-
Gdansk, Pomorskie, Poland, 80-211
- Recruiting
- Medical University of Gdańsk, Department of Cardiac Anesthesiology
-
Contact:
- Romuald Lango, M.D., Ph.D.
- Phone Number: +48583492483
- Email: rlango@gumed.edu.pl
-
Contact:
- Maciej Kowalik, M.D., Ph.D.
- Phone Number: +48583492483
- Email: mkowalik@gumed.edu.pl
-
Sub-Investigator:
- Wiktor Szymanowicz, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- adult patients
- signed informed consent
- scheduled for elective on-bypass cardiac surgery (aortic valve surgery, mitral valve surgery with/without tricuspid valve surgery, ascending aorta surgery with/without aortic valve surgery).
Exclusion Criteria:
- chronic kidney insufficiency (serum creatinine >2 mg/dL)
- active infection (i.e.: endocarditis)
- shock or tissue hypoperfusion before operation (blood lactate >3 mmol/L)
- left ventricle ejection fraction <25%
- vancomycin used for infection prophylaxis (i.e.: in immunosuppressed patients)
- history of ischaemic shock
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
BRAIN+THENAR MUSCLE INVOS
Patients undergoing open heart surgery on cardiopulmonary bypass.
|
Brain oximetry and tissue saturation will be measured during operation.
NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NGAL
Time Frame: 3 hours after operation
|
neutrophil gelatinase-associated lipocalin (NGAL) measured in blood samples
|
3 hours after operation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NGAL on second day
Time Frame: second post-op day morning
|
neutrophil gelatinase-associated lipocalin (NGAL) measured in blood samples
|
second post-op day morning
|
|
Cystatin C
Time Frame: second post-op day morning
|
Cystatin-C measured in blood samples
|
second post-op day morning
|
|
Serum creatinine
Time Frame: second post-op day morning
|
Serum creatinine in serum
|
second post-op day morning
|
|
Acute renal failure
Time Frame: 30 day / any time after operation before discharge from hospital
|
Acute renal failure requiring renal replacement therapy or AKIN stage 3
|
30 day / any time after operation before discharge from hospital
|
|
In hospital mortality
Time Frame: 30 day / any time after operation before discharge from hospital
|
Death from any reason.
|
30 day / any time after operation before discharge from hospital
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Romuald Lango, M.D., Ph.D., Medical University of Gdańsk, Department of Cardiac Anesthesiology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NKEBN/122/2014
- grant ST-44 (Other Grant/Funding Number: Medical University of Gdansk)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.